Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII

被引：25
|
作者：
Scharrer, I
Ehrlich, HJ
机构：
[1] Univ Hosp Frankfurt, Ctr Internal Med, D-60596 Frankfurt, Germany
[2] Baxter Hyland Immuno, Vienna, Austria
来源：
HAEMOPHILIA | 2001年 / 7卷 / 04期
关键词：
blood coagulation factor inhibitors; clinical trials; factor VIII; haemophilia A; incidence; recombinant proteins;
D O I：
10.1046/j.1365-2516.2001.00515.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
De novo inhibitor development is a rare event in PTPs switched from pdFVIII to rFVIII. Based on previously published data of clinical studies a change in FVIII product is unlikely to provoke inhibitor formation.
引用
收藏
页码：346 / 348
页数：3
相关论文
共 50 条
  • [41] Multicenter comparison of inhibitor (Inh) development on plasma-derived (PD) vs recombinant (rec) factor VIII(fVIII) in severe hemophilia a patients (sHA pts).
    DiMichele, D
    Rothschild, C
    Sultan, Y
    Kroner, B
    Aledort, L
    BLOOD, 1999, 94 (10) : 238A - 238A
  • [42] Effect of recombinant and plasma-derived von Willebrand Factor on the procoagulant activity of factor VIII in thrombin generation assays
    Knappe, Sabine
    Till, Susanne
    Scheiflinger, Friedrich
    Dockal, Michael
    HAEMOPHILIA, 2014, 20 : 28 - 28
  • [43] Interferon-gamma secretion defects in haemophilia A patients receiving highly purified plasma-derived or recombinant factor VIII
    NewtonNash, DK
    Tollerud, D
    Guevarra, L
    Gill, JC
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (03) : 554 - 560
  • [44] A Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2010, 52 (1340): : 46 - 47
  • [45] INCIDENCE OF FACTOR-VIII INHIBITOR DEVELOPMENT IN SEVERE HEMOPHILIA-A PATIENTS TREATED ONLY WITH ONE BRAND OF HIGHLY PURIFIED PLASMA-DERIVED CONCENTRATE
    GUEROIS, C
    LAURIAN, Y
    ROTHSCHILD, C
    PARQUETGERNEZ, A
    DUCLOS, AM
    NEGRIER, C
    VICARIOT, M
    FIMBEL, B
    FRESSINAUD, E
    FIKSSIGAUD, M
    DERLON, A
    BERTHIER, AM
    GAILLARD, S
    BERTRAND, MA
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (02) : 215 - 218
  • [46] Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States
    Neufeld, Ellis J.
    Sidonio, Robert F., Jr.
    O'Day, Ken
    Runken, M. Chris
    Meyer, Kellie
    Spears, Jeffrey
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 762 - 769
  • [47] Viral safety of plasma-derived factor VIII and IX concentrates
    Ludlam, CA
    BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 : S19 - S23
  • [48] Cellular Stress Induced by Plasma-Derived Factor VIII Products
    Brodde, Martin
    Mueller, Anja
    Kehrel, Beate
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2014, 41 (02) : 140 - 144
  • [49] VIRAL SAFETY ISSUES - PLASMA-DERIVED FACTOR-VIII
    BERNTORP, E
    ANNALS OF HEMATOLOGY, 1994, 68 : S35 - S36
  • [50] Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice
    Qadura, Mohammad
    Waters, Braden
    Burnett, Erin
    Chegeni, Rouzbeh
    Bradshaw, Scott
    Hough, Christine
    Othman, Maha
    Lillicrap, David
    BLOOD, 2009, 114 (04) : 871 - 880
12345